3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
4
Prostatic Neoplasms
2
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Smoking Cessation
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms
1
Motor Activity
1
Lung Neoplasms
1
Liver Cirrhosis
1
Leukemia, Hairy Cell
1
Inflammation
1
Hemorrhage
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Carcinoma
1
Breast Neoplasms
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
15
pembrolizumab
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
10
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Paclitaxel
7
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Aspirin
×
90 days
×
Clear all
NCT07529262
2026-04-14
AspiRe HCC
Curtin University
Phase 3
Not yet recruiting
890 enrolled